Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection

Ruben J. Mylvaganam, Joseph I. Bailey, Jacob I. Sznajder, Marc A. Sala

Source: Eur Respir Rev, 30 (162) 210194; 10.1183/16000617.0194-2021

Journal Issue: December

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ruben J. Mylvaganam, Joseph I. Bailey, Jacob I. Sznajder, Marc A. Sala. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev, 30 (162) 210194; 10.1183/16000617.0194-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Role of influenza virus infection in lung fibrosis Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease Year: 2010
Epidemic and pandemic viral infections: impact on tuberculosis and the lung Source: Eur Respir J, 56 (4) 2001727; 10.1183/13993003.01727-2020 Year: 2020
Association between influenza vaccination and the occurrence of acute exacerbation in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Particularities of pulmonary tuberculosis during the COVID-19 pandemic Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Frequency and pathogenicity of rhinovirus associated pulmonary exacerbations in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013
Malaria and the development of pulmonary fibrosis Source: Eur Respir J, 50 (6) 1702030; 10.1183/13993003.02030-2017 Year: 2017
Influenza A virus in exacerbation of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 152s Year: 2001
Influenza vaccine-induced interstitial lung disease Source: Eur Respir J 2013; 41: 474-477 Year: 2013
ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Assessment Source: ERS webinar 2020: ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Assessment Year: 2020
Respiratory viral agents in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
ERS/ATS joint webinar: Rehabilitation after COVID 19 disease Source: ERS webinar 2020: ERS/ATS joint webinar: Rehabilitation after COVID 19 disease Year: 2020
Severe influenza virus H1N1: Lung pathology Source: Annual Congress 2010 - Influenza A (H1N1): epidemiology Year: 2010
Update on management of lung infection in cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020
Influenza and pneumococcal vaccines prevalence and their influance on asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Programme Source: ERS webinar 2020: ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Programme Year: 2020
The role of hepatitis C virus infections in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 333s Year: 2005
The challenge of acute exacerbation of pulmonary fibrosis Source: International Congress 2014 – PG01 Challenges faced when diagnosing idiopathic interstitial lung disease Year: 2014
Emergencies in interstitial and immunological lung disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-42-1, page=177 Year: 2006
Modelling pulmonary fibrosis Source: Annual Congress 2012 - PG4 Experimental models for respiratory medicine: strengths and limitations Year: 2012